FDA Brief

Warning letters Drugs

FDA warning letter to

Lex Inc.

High riskIssued Aug 17, 2023Posted Sep 5, 2023Division of Pharmaceutical Quality Operations II

FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

What happened

FDA inspected Lex Inc.'s drug manufacturing facility in Medley, Florida, from February 13 to February 28, 2023. The agency found significant current good manufacturing practice (CGMP) violations, including inadequate quality unit oversight, missing identity testing for glycerin and propylene glycol at risk of diethylene glycol (DEG) and ethylene glycol (EG) contamination, incomplete process validation, unqualified equipment, weak laboratory data controls, and inadequate scale calibration. FDA reviewed the firm's March 22, 2023 response and found it inadequate.

What FDA found

  1. The quality unit failed to oversee drug manufacturing, approve or reject components and products, review records, and ensure CGMP compliance.

    21 CFR 211.22
  2. The firm did not adequately test incoming components, including identity testing for glycerin and propylene glycol at risk of DEG/EG contamination, and did not qualify suppliers.

    21 CFR 211.84(a), 211.84(d)(1), 211.84(d)(2)
  3. The firm lacked adequate written production and process control procedures and had incomplete process validation studies.

    21 CFR 211.100(a)
  4. Manufacturing equipment was not qualified, laboratory computer systems allowed uncontrolled data changes, and production scales were not adequately calibrated.

    21 CFR 211.68(a) and (b)

What FDA wants

FDA tells Lex to provide a comprehensive assessment and remediation plan covering its quality unit, component testing, supplier qualification, process validation, equipment qualification, calibration, and data integrity, including risk assessments and recalls for any DEG/EG-contaminated lots. FDA also strongly recommends engaging a qualified CGMP consultant; the letter does not state a response deadline.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • retailers and distributors of pediatric OTC cough and cold products
  • suppliers and contract labs testing glycerin or propylene glycol

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk